The global antidiabetic drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The disease burden of diabetes is high and growing in every country, fueled by an increase in the prevalence of obesity and unhealthy lifestyles throughout the globe. The market growth is attributed owing to the rising incidence of diabetes and the growing number of health awareness initiatives launched by various health organizations. Presently, type-1 diabetes accounts for roughly 10% of all the global diabetes cases (with type-2 accounting for the remaining share). The factor contributing to the growth of the global antidiabetic drugs market include the rising healthcare expenditure on the disease. According to the International Diabetes Federation (IDF), the annual global health spending on diabetes was about $760 billion in 2019.

Some key players operating in the market include Eli Lilly and Co., AstraZeneca plc, and Sanofi S.A., among others. The market players are eyeing to strengthen their position in the market by adopting various strategies such as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended-release tablets) was authorized by the US FDA in January 2020 to reduce blood sugar in individuals with type-2 diabetes. Trijardy XR is a combination of three type-2 diabetes medications in a single tablet. Novo Nordisk announced in September 2019 that the US FDA had authorized Rybelsus (semaglutide) oral tablets for adult patients with type 2 diabetes. Rybelsus is the first non-injected glucagon-like peptide (GLP-1) receptor protein therapy to get FDA clearance in the US.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Diabetes Type 
• By Patient Type

Regions covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape:  Eli Lilly and Co., AstraZeneca plc, and Sanofi S.A., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Antidiabetic Drugs Market Report by Segment

By Diabetes Type

• Type 1 Diabetes
• Type 2 Diabetes

By Patient Type

• Adult
• Pediatric
• Geriatric

Global Antidiabetic Drugs Market Report by Region

North America       

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa